



CORRIGENDUM

Corrigendum to “Italian Titration Approach Study (ITAS) with insulin glargine 300 U/mL in insulin-naïve type 2 diabetes: Design and population” [Nutr Metabol Cardiovasc Dis 29 (5) (May 2019) 496–503]



R.C. Bonadonna <sup>a,\*</sup>, A. Giaccari <sup>b</sup>, R. Buzzetti <sup>c</sup>, G. Aimaretti <sup>d</sup>, D. Cucinotta <sup>e</sup>, A. Avogaro <sup>f</sup>, G. Perseghin <sup>g</sup>, M. Larosa <sup>h</sup>, G.B. Bolli <sup>i</sup>, C.G. Fanelli <sup>i</sup>

<sup>a</sup> Division of Endocrinology and Metabolic Diseases, Department of Medicine and Surgery, University of Parma, AOU of Parma, Italy

<sup>b</sup> Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome and Università Cattolica del Sacro Cuore, Rome, Italy

<sup>c</sup> Sapienza University of Rome, Italy

<sup>d</sup> University of the Eastern Piedmont, Italy

<sup>e</sup> University of Messina, Italy

<sup>f</sup> University of Padua, Italy

<sup>g</sup> University of Milan Bicocca, Italy

<sup>h</sup> Sanofi, Milan, Italy

<sup>i</sup> Section of Endocrinology and Metabolism, Department of Medicine, Perugia University Medical School, Italy

The authors regret that the Conflict of Interest statement is incorrect and should read as follows:

**Conflict of interest**

RCB has reported personal fees from Sanofi Italy and France; Merck Sharp & Dohm Italy; Eli Lilly Italy and U.S.A; Johnson & Johnson Italy; Bristol-Myers Squibb Italy; AstraZeneca Italy, Janssen, Italy; during the conduct of the study.

AG has reported personal fees from Sanofi, Italy, France and US; during the conduct of the study; personal fees from Amgen, Italy; AstraZeneca, Italy; Boehringer Ingelheim, Italy; Eli-Lilly, Italy; MSD, Italy; Sanofi Giordania, Lebanon, Egypt (outside the submitted work) and grants from AstraZeneca, Italy.

RB has reported personal fees from Sanofi, Italy and France; Eli Lilly, Italy; Abbott, Italy; Novo Nordisk, Italy; outside the submitted work.

GA has reported grants and personal fees from Sanofi, Italy; AstraZeneca, Italy; personal fees from IBSA, Italy; Novartis Italy; grants from Novo Nordisk, Italy, during the conduct of the study.

DC has reported personal fees from Eli Lilly Italy; Novo Nordisk, Italy; Sanofi, Italy.

AA has reported personal fees from Novo Nordisk, Italy; Eli Lilly, Italy; Sanofi, Italy, grants and personal fees from AstraZeneca, Italy; personal fees from Boehringer Ingelheim, Italy; Takeda, Italy; personal fees from Servier, France, grants and personal fees from Vifor Pharma, Switzerland, outside the submitted work.


DOI of original article: <https://doi.org/10.1016/j.numecd.2019.01.011>.

\* Corresponding author. Division of Endocrinology and Metabolic Diseases, Department of Medicine and Surgery, University of Parma, AOU of Parma, Via Gramsci 14, Parma, 43126, Italy.

E-mail address: [Italy.riccardo.bonadonna@unipr.it](mailto:Italy.riccardo.bonadonna@unipr.it) (R.C. Bonadonna).

<https://doi.org/10.1016/j.numecd.2019.05.059>

0939-4753/© 2019 Published by Elsevier B.V. on behalf of The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University.



GP has reported personal fees from Sanofi, Italy; Eli Lilly, Italy; AstraZeneca, Italy; Takeda, Merck, Italy; Abbott, Italy; Novo Nordisk, Italy; Boheringer Ingelheim, Italy; Janssen Italy; outside the submitted work.

ML is employee/shareholder of Sanofi, Italy

GBB has reported grants and personal fees from Sanofi Italy and France; personal fees from Menarini, Italy; during the conduct of the study.

CGF has reported personal fees from Sanofi, Italy; non-financial support from Menarini, Italy; outside the submitted work.

The authors also regret that Figure 2 was incorrect, and should be as follows:

The authors would like to apologise for any inconvenience caused.